mobic and Escherichia-coli-Infections

The clinical and anti-inflammatory effects of a single treatment of 0.4 mg meloxicam/kg bodyweight on pigs that had been challenged with Escherichia coli endotoxin were investigated. Significantly lower total clinical scores were recorded in pigs treated with meloxicam than in pigs treated with a placebo. Significantly higher mean serum concentrations of thromboxane B(2) were also recorded in pigs treated with a placebo for up to 24 hours after the challenge. The serum concentrations of acute phase proteins and specific antibody titres to E coli lipopolysaccharide were unaffected by the meloxicam. The meloxicam treatment was well tolerated.

Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Bacterial; Endotoxemia; Escherichia coli; Escherichia coli Infections; Female; Immunoglobulin G; Lipopolysaccharides; Male; Meloxicam; Single-Blind Method; Swine; Swine Diseases; Thiazines; Thiazoles; Thromboxane B2; Treatment Outcome